ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Oct 18, 2026, 13:0810 Posts Not to Miss This Week
-
Oct 18, 2026, 12:58Pierpaolo Di Micco: DOACs vs Vitamin K Antagonists in Long-Term Anticoagulation
-
Oct 18, 2026, 12:51Arianne Missimer: Understanding Ferritin Levels Beyond the Normal Range
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab
-
Oct 18, 2026, 12:26Abdul Mannan: When INR Misleads – Rethinking Bleeding Risk in Cirrhosis
-
Oct 18, 2026, 12:14Stéphane Laurent: The People and Technology Behind Safe Blood Transfusion
-
Oct 18, 2026, 12:14Abhi Kapuria: When VTE Prophylaxis Breaks Down in the ICU
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety